Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of 2C-D can be broken down into several components which progressively intensify proportional to dosage.
The head space of 2C-D is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages. The feeling of "unaltered consciousness" may be bothersome to trippers that are willing to experience events and concepts from a shifting point of view, since on 2C-D everything is fairly normal, stable and therefore rather uninteresting.
2C-D presents a full and complete array of possible visual distortions.
2C-D presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of DOM or 25D-NBOMe than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in style, intricate in complexity, large in size, slow and smooth in motion, colourful in scheme, bright in colour, blurred in its edges and equally rounded and angular in its corners. They give off a natural feel to them at higher dosages. Whilst the final level of 2C-D geometry 2C-D has yet to be formally confirmed, it seems more likely that it would result in states of Level 8B visual geometry over Level 8A.
2C-D produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family.
The auditory effects of 2C-D are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-D is not habit-forming and the desire to use it can actually decrease with use. It is described as self-regulating and is not known to be associated with compulsive use patterns.
Physical dependence is considered extremely unlikely. No withdrawal syndrome has been documented.
The exact toxic dose is unknown due to 2C-D's status as a research chemical with very limited history of human usage. There are reported cases of users significantly exceeding typical dosing limits without lasting adverse physical effects.
Severe mental confusion and paranoia are listed among possible negative effects at higher doses, though specific psychosis risk from 2C-D alone has not been systematically studied.
The synthesis of 2C-D was first documented in scientific literature by Beng T. Ho and colleagues at the Texas Research Institute of Mental Sciences in 1970, who described both its preparation and pharmacological activity in animals. However, Alexander Shulgin had already begun human trials of the…
Subject to a blanket ban covering all substituted phenethylamines, including the entire 2C-X family of compounds.
Listed on Portaria SVS/MS nº 344 as of February 18, 2014. Possession, production, and sale are prohibited.
Controlled as of October 2015. Sale, purchase, importation, exportation, and manufacture are prohibited.
Banned in December 2014 under a government decree on psychoactive substances prohibited from the consumer market.
Added to the national list of controlled substances in December 2008, making purchase, sale, and possession illegal.
Listed as a Schedule I controlled substance under Latvian drug control legislation.
Classified as a health hazard by the Statens folkhälsoinstitut under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor) as of March 1, 2005, in regulation SFS 2005:26. Sale and possession are illegal.
Classified as a drug under Turkish law. Possession, production, supply, and importation are prohibited.
Federally controlled under the Controlled Substances Act since July 9, 2012, when the Food and Drug Administration Safety and Innovation Act was signed into law. Manufacturing, buying, possessing, or distributing requires a DEA license. Additionally controlled at state level in Alabama, Florida, Louisiana, Oklahoma, Pennsylvania, and Vermont.
Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Schedule II of the accompanying NPSV regulation explicitly bans all substituted phenethylamines.
Controlled under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016, as a derivative of 2,5-dimethoxyphenethylamine.
Listed as a Schedule B controlled substance under Danish drug legislation.
Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of December 13, 2014. Manufacturing, possession, importation, exportation, purchase, sale, procurement, and dispensation without a license is prohibited.
Regulated under the Pharmaceutical Affairs Law, making possession and sale illegal.
Currently not controlled, though it falls within a substance group that may be prohibited under recently enacted New Psychoactive Substances legislation.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971 as a result of the phenethylamine catch-all clause, which covers substituted phenethylamine derivatives.
17 sources cited
